November 21, 2026
$RichWire Markets and money, explained simply
LIVE
Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results

Viking Therapeutics Advances Weight Loss Drug With Four Phase 3 Trials Underway

🧠 AI Analysis 1 min read 👁 2

Biotech firm Viking Therapeutics is advancing its experimental obesity treatment VK2735 through four Phase 3 trials, aiming to tap into a high-demand market dominated by blockbusters like Eli Lilly's Zepbound.

Viking Therapeutics Advances Weight Loss Drug With Four Phase 3 Trials Underway🧠AI Analysis

Photo: Motley Fool

Key points

  • Viking Therapeutics has four Phase 3 trials underway for its VK2735 obesity drug.
  • The trials test both subcutaneous and oral formulations, with results expected in 2027 and 2028.
  • The company raised $547.8 million following encouraging mid-stage trial results.
  • Key risks include managing side-effect tolerability and competing against rival blockbusters.

Biotechnology company Viking Therapeutics is currently advancing its flagship experimental weight-loss drug, VK2735, through four active Phase 3 trials. The ongoing studies evaluate both subcutaneous and oral formulations of the treatment for obesity and obesity combined with type 2 diabetes, with clinical results anticipated between 2027 and 2028.

Management's clinical strategy centers on offering flexible dosing options. This includes a potential dual formulation approach where patients could start with subcutaneous injections for rapid initial weight reduction and transition to a more convenient oral form for maintenance. The company recently raised a net $547.8 million through a stock and convertible senior notes offering following positive mid-stage data.

While early data from a small maintenance study showed promising weight-loss figures—reaching 21.7% in an exploratory cohort—analysts note significant hurdles remain. Previous tests of the oral formulation showed a 20% discontinuation rate due to adverse events, meaning future trials must prove both high efficacy and better patient tolerability to compete against established market giants like Eli Lilly and Novo Nordisk.

What to watch next: Investors should monitor the upcoming results from the second part of the ongoing maintenance study, which evaluates the transition from subcutaneous to oral dosing.

Source Motley Fool — fool.com/investing/2026/11/18/have-1000-this-beaten-down-biotech-ha… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.